Opinion
Video
B Cells as a Treatment Target In Myasthenia Gravis
Author(s):
Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.
Time Codes
2:09 Pathophysiology of MG
6:32 Up/Downstream MG Targets
10:26 Recent Approvals in MG
14:20 B-Cell Targets in MG
17:07 Inebilizumab in MG
19:55 Anti-CD19 Targets in MG
23:11 Safety of MG Therapies
25:26 Role of Targeted Tx in MG
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
